Article

B&L launches Stellaris vision enhancement system

The Stellaris vision enhancement system from Bausch & Lomb (B&L) is designed to meet current and future needs of the contemporary phacoemulsification surgeon, according to the company. B&L engineers reportedly designed the system based on the input of existing customers worldwide who were queried to create a list of desired new features and changes to existing technology. The result is a machine that is compact, mobile, and extremely user-friendly, provides advanced fluidics and power modulation technology, and overall yields superior control and intraoperative efficiency.

The Stellaris vision enhancement system from Bausch & Lomb (B&L) is designed to meet current and future needs of the contemporary phacoemulsification surgeon, according to the company. B&L engineers reportedly designed the system based on the input of existing customers worldwide who were queried to create a list of desired new features and changes to existing technology. The result is a machine that is compact, mobile, and extremely user-friendly, provides advanced fluidics and power modulation technology, and overall yields superior control and intraoperative efficiency.

The system allows customizable preferences for vacuum or flow-based fluidics and supports standard small-incision coaxial phaco, as well as microincision surgery using coaxial or bimanual modes. In addition, it is designed to be fully adaptable for future upgrades, eliminating the frustration of investing in new technology that too soon becomes outdated.

According to Bausch & Lomb, the system features many innovations, including a redesigned, ergonomic, ultralight titanium handpiece. In addition, it offers an 18-inch, high-resolution, touch-screen display with a large font size that is easily visible from across the operating room. The display also provides a choice of different formats, features a streaming video inlay, and shows an animated guide providing complete set-up instructions. The system's venturi pump is able to reach a vacuum level of 600 mm Hg.

For more information, visit Bausch & Lomb at Booth 1641.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.